|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current Assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Installment Receivable (Current Portion) & Investments | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Accrued Interest Receivable | ||||||||||||||||||||
| Investments - unrelated parties | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Total investments - unrelated parties | ||||||||||||||||||||
| Fixed assets - net | ||||||||||||||||||||
| Long term Notes Receivable - related parties | ||||||||||||||||||||
| Entrepreneurship Development | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total long term Notes Receivable - related parties | ||||||||||||||||||||
| Other Notes Receivable - related parties | ||||||||||||||||||||
| Long term Investments - related parties | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total long term Investments - related parties | ||||||||||||||||||||
| Installment Receivable | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Marginal loan payable | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Long-Term Liabilities: | ||||||||||||||||||||
| Notes payable | ||||||||||||||||||||
| Line of credit - related party | ||||||||||||||||||||
| Long-term liability payable | ||||||||||||||||||||
| Long-Term Liabilities - Notes payable | ||||||||||||||||||||
| Common stock ($0.001 par value) | ||||||||||||||||||||
| Preferred stock, $.001 par value, 1,000,000 and 10,000,000 shares authorized, 1 issued and outstanding as at December 31, 2020 and 2019 respectively. | ||||||||||||||||||||
| Common Stock, $0.001 par value, 1,200,000,000 and 200,000,000 shares authorized, 177,922,436 and 169,922,436 issued and outstanding as at December 31, 2020 and 2019 respectively. | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||||||||||||||
| Common Stock, $0.001 par value, 200,000,000 shares authorized, 182,370,497 issued and outstanding as at June 30, 2025 and December 31, 2024. | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Stockholders’ Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders’ Equity | ||||||||||||||||||||
Loading...